Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 143 entries
View as:

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT04273945 Org: User:
Start: 06/30/20 End: 02/20/29 Due: 02/20/30

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02206204 Org: User:
Start: 06/30/12 End: 11/30/12 Due: 11/30/13

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03232073 Org: User:
Start: 07/05/17 End: 01/16/24 Due: 01/16/25

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401

Phase: N/A Priority: Normal
NCT ID: NCT01105117 Org: User:
Start: 05/31/10 End: 12/31/11 Due: 12/31/12

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Phase: N/A Priority: Normal
NCT ID: NCT03942211 Org: User:
Start: 02/26/21 End: 04/19/23 Due: 04/19/24

Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02476864 Org: User:
Start: 08/31/15 End: 12/31/15 Due: 12/31/16

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT02254954 Org: User:
Start: 01/08/15 End: 09/29/16 Due: 09/29/17

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04914247 Org: User:
Start: - End: - Due: -

Bosentan in Children With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00319267 Org: User:
Start: 05/31/05 End: 02/28/07 Due: 02/28/08

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00709098 Org: User:
Start: 09/30/08 End: 06/30/10 Due: 06/30/11

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02029482 Org: User:
Start: 04/30/10 End: 06/30/10 Due: 06/30/11

The Effect of Tracleer® on Male Fertility

Phase: N/A Priority: Normal
NCT ID: NCT00082186 Org: User:
Start: 07/31/03 End: 11/30/07 Due: 11/30/08

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT02932410 Org: User:
Start: 10/24/17 End: 11/30/25 Due: 11/30/26

Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00313222 Org: User:
Start: 10/31/05 End: 03/31/07 Due: 03/31/08

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT03187678 Org: User:
Start: 12/04/17 End: 05/29/18 Due: 05/29/19

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

Phase: N/A Priority: Normal
NCT ID: NCT01822028 Org: User:
Start: 03/31/13 End: 08/31/13 Due: 08/31/14

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT03904693 Org: User:
Start: 07/29/19 End: 09/27/24 Due: 09/27/25

A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Phase: N/A Priority: Normal
NCT ID: NCT03422328 Org: User:
Start: 04/05/18 End: 12/27/23 Due: 12/27/24

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02471183 Org: User:
Start: 10/12/15 End: 12/05/16 Due: 12/05/17

A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04963439 Org: User:
Start: 07/08/21 End: 10/05/21 Due: 10/05/22

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

Phase: N/A Priority: Normal
NCT ID: NCT02206295 Org: User:
Start: 09/30/12 End: 12/31/12 Due: 12/31/13

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT02382016 Org: User:
Start: 06/23/15 End: 10/31/18 Due: 10/31/19

Bosentan in Systemic Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01395732 Org: User:
Start: 03/31/11 End: 12/31/12 Due: 12/31/13

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00667823 Org: User:
Start: 10/17/08 End: 12/07/20 Due: 12/07/21

A Registry for Patients Taking Uptravi

Phase: N/A Priority: Normal
NCT ID: NCT03278002 Org: User:
Start: 11/01/16 End: 09/21/21 Due: 09/21/22